Document is current
Any future updates will be listed below
-
Authors
Chen, Yanan https://orcid.org/0000-0001-5510-231X
Kunjamma, Rejani B.
Lin, Karin https://orcid.org/0000-0003-2789-2996
Kai, Li
Dima, Maria
Bruce, Kody https://orcid.org/0009-0001-0601-4687
Steckler, Ian
Che, Young Hyun https://orcid.org/0000-0002-0355-4055
Chan-Zervas, Jason
Eugenin von Bernhardi, Jaime
Connelly, Caitlin
Ece, Sude
Newell, Grace https://orcid.org/0009-0002-7859-1456
Bergles, Dwight E. https://orcid.org/0000-0002-7133-7378
Sidrauski, Carmela https://orcid.org/0000-0002-4850-3112
Popko, Brian https://orcid.org/0000-0001-9948-2553
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (5R01NS034939)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (1R35NS137478)
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
the Rampy MS Research Foundation.
National Multiple Sclerosis Society (TA-2008-37043)
- License Information
-
More Information
Article History
Received: 28 September 2024
Accepted: 16 December 2025
First Online: 26 December 2025
Competing interests
: Brian Popko is on the scientific advisory board of InFlectis Biosciences, which has an interest in modulating the ISR for neurodegenerative disorders. There is no conflict with the current study. Rejani B. Kunjamma, Karin Lin, and Caitlin F. Connelly (at time of contribution) are employees of Calico Life Sciences LLC and have no additional financial interests to declare. Carmela Sidrauski is an employee of Calico Life Sciences LLC and is listed as an inventor on a patent application WO2017193063 describing 2BAct. 2BAct was used in this study to treat Jimp y mice. This composition of matter patent covering 2BAct and related analogs has been published. The remaining authors declare no competing interests.
